Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma

F. Merli, M. Bertini, S. Luminari, R. Mozzana, B. Botto, A. M. Liberati, L. Baldini, G. Cabras, F. Di Vito, L. Orsucci, E. Naglieri, G. Polimeno, L. Marcheselli, E. Pennese, U. Vitolo, M. Federico, E. Gallo

Research output: Contribution to journalArticle

Abstract

The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54% vs 66% (p = 0.107) and 90% vs 78% (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32%, 52%, and 21%, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.

Original languageEnglish
Pages (from-to)367-373
Number of pages7
JournalLeukemia and Lymphoma
Volume48
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Survival
Quality of Life
B-Cell Lymphoma
B-Lymphocytes
Therapeutics
Monoclonal Antibodies
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. / Merli, F.; Bertini, M.; Luminari, S.; Mozzana, R.; Botto, B.; Liberati, A. M.; Baldini, L.; Cabras, G.; Di Vito, F.; Orsucci, L.; Naglieri, E.; Polimeno, G.; Marcheselli, L.; Pennese, E.; Vitolo, U.; Federico, M.; Gallo, E.

In: Leukemia and Lymphoma, Vol. 48, No. 2, 02.2007, p. 367-373.

Research output: Contribution to journalArticle

Merli, F, Bertini, M, Luminari, S, Mozzana, R, Botto, B, Liberati, AM, Baldini, L, Cabras, G, Di Vito, F, Orsucci, L, Naglieri, E, Polimeno, G, Marcheselli, L, Pennese, E, Vitolo, U, Federico, M & Gallo, E 2007, 'Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 48, no. 2, pp. 367-373. https://doi.org/10.1080/10428190601078100
Merli, F. ; Bertini, M. ; Luminari, S. ; Mozzana, R. ; Botto, B. ; Liberati, A. M. ; Baldini, L. ; Cabras, G. ; Di Vito, F. ; Orsucci, L. ; Naglieri, E. ; Polimeno, G. ; Marcheselli, L. ; Pennese, E. ; Vitolo, U. ; Federico, M. ; Gallo, E. / Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2007 ; Vol. 48, No. 2. pp. 367-373.
@article{545a3f8379f14d09af4824829932604a,
title = "Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma",
abstract = "The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54{\%} vs 66{\%} (p = 0.107) and 90{\%} vs 78{\%} (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32{\%}, 52{\%}, and 21{\%}, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.",
author = "F. Merli and M. Bertini and S. Luminari and R. Mozzana and B. Botto and Liberati, {A. M.} and L. Baldini and G. Cabras and {Di Vito}, F. and L. Orsucci and E. Naglieri and G. Polimeno and L. Marcheselli and E. Pennese and U. Vitolo and M. Federico and E. Gallo",
year = "2007",
month = "2",
doi = "10.1080/10428190601078100",
language = "English",
volume = "48",
pages = "367--373",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma

AU - Merli, F.

AU - Bertini, M.

AU - Luminari, S.

AU - Mozzana, R.

AU - Botto, B.

AU - Liberati, A. M.

AU - Baldini, L.

AU - Cabras, G.

AU - Di Vito, F.

AU - Orsucci, L.

AU - Naglieri, E.

AU - Polimeno, G.

AU - Marcheselli, L.

AU - Pennese, E.

AU - Vitolo, U.

AU - Federico, M.

AU - Gallo, E.

PY - 2007/2

Y1 - 2007/2

N2 - The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54% vs 66% (p = 0.107) and 90% vs 78% (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32%, 52%, and 21%, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.

AB - The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54% vs 66% (p = 0.107) and 90% vs 78% (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32%, 52%, and 21%, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.

UR - http://www.scopus.com/inward/record.url?scp=34247843100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247843100&partnerID=8YFLogxK

U2 - 10.1080/10428190601078100

DO - 10.1080/10428190601078100

M3 - Article

C2 - 17325898

AN - SCOPUS:34247843100

VL - 48

SP - 367

EP - 373

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -